

International Summit on Lung Cancer

DATE: Rome May 8-9, 2022 SEDE:

LE MERIDIEN VISCONTI

TIPOLOGIA: Convegno residenziale con accreditamento ECM

Figure accreditate: Medico Chirurgo (Allergologia e Immunologia clinica, Anatomia Patologica, Chirurgia Generale, Chirurgia Toracica, Cure Palliative, Direzione Medica di Presidio Ospedaliero, Farmacologia e Tossicologia clinica, Genetica Medica, Malattie dell'Apparato Respiratorio, Medicina Interna, Medicina Nucleare, Oncologia, Patologia Clinica, Radiodiagnostica, Radioterapia) – **Farmacista** (Farmacia Ospedaliera, Farmacia Territoriale) – **Biologo - Fisico sanitario - Tecnico Sanitario Laboratorio Biomedico - Tecnico Sanitario Radiologia Medica - Tecnico della fisiopatologia cardiocircolatoria e perfusione cardiovascolare - Infermiere**

Numero partecipanti previsti: 80

CONGRESSO ACCREDITATO ECM PER LE GIORNATE 8-9 MAGGIO 2022

Scientific Committee: Federico Cappuzzo, Silvia Novello, Giorgio Scagliotti

Scientific Secretariat: Lorenza Landi, Gabriele Minuti

RATIONAL

Lung cancer represents in Italy the first cause of death from cancer in males and the third cause in women. Lung cancer treatment is based on the multidisciplinary integration of surgical, medical and oncological specialties.

The correct definition of the molecular profile of lung cancer patients has become the key point for designing the best therapeutic path to offer to patients.

The personalization of treatments can no longer disregard the complete characterization of clinically relevant alterations, such as EGFR mutations, ALK and ROS1 translocations and evaluation of PD-L1 expression.

In this event, the leading experts in the field of lung cancer discuss clinical questions, with a view to a complete multidisciplinary, with particular attention to current and future therapeutic options.

Program day 1: May 8th, 2022

09.00-10.00: Registration

10.00-10.15: Message of IFO Scientific Director: Gennaro Ciliberto

10.15-11-15: Prevention and early detection of lung cancer

Chair: Lucio Crinò and Ugo Pastorino

10.15-10.35: Tobacco cessation among patients with lung cancer: April Plank

10.35-10.55: Radon as risk factor in lung cancer: Laura Mezquita

10.55-11.15: Early detection of lung cancer: Ugo Pastorino

11.15-12.00: Liquid biopsy and new biomarkers

Chair: Fred Hirsch and Nicola Normanno

11.15-11.30: Liquid biopsy for screening and early detection: Gabriella Sozzi

11.30-11.45: Liquid biopsy for guiding therapy decision: Umberto Malapelle

11.45-12.00: Neoantigen landscape and Tumor Mutational Burden: Patrick Alexander Ott

12.00-13.00: Neoadjuvant therapy of lung cancer

Chair: Domenico Galetta and Francesco Grossi

12.00-12.10: CheckMate 816 trial: Jonathan Spicer

12.10-12.20: Neoadjuvant with single agent immunotherapy: Jair Bar

12.20-12.30: Studies with neoadjuvant target therapy: Masahiro Tsuboi

12.30 – 12:40: Minimal Residual Disease assessment with Liquid Biopsy
Christian Rolfo

12.40-12.50: Pathological assessment following neoadjuvant therapy: Sanja Dacic

13.00-14.00: Lunch

14.00-15.00: Adjuvant therapy**Chair: Giorgio Scagliotti and Anne-Marie C Dingemans**

14.00-14.10: First-generation EGFR-TKIs in EGFR mutant NSCLC: Yi Long Wu

14.10-14.20: Osimertinib in surgically resected EGFR mutant NSCLC: Christian Grohe (Germany)

14.20-14.30: Emerging target therapies in surgically resected NSCLC Maurice Perol (France)

14.30-14.40: Atezolizumab in resected NSCLC: Enriqueta Felip (Spain)

14.40-14.50: Other checkpoint inhibitors for resected NSCLC: Simon Ekman (Sweden)

14.50-15.00: Canakinumab in early stage NSCLC: Giulia Pasello

15.00-16.00: Integrated therapies for stage III NSCLC**Chair: Sara Ramella and Andrea Filippi**

15.00-15.10: Radiotherapy for N2 resected NSCLC: Cecile Le Pechoux (France)

15.10-15.20: 5 years OS in PACIFIC trial: Andrea Filippi (Italy)

15.20-15.30: PACIFIC real world data: Nicolas Girard (France)

15.30-15.40: Coast trial: Fabrice Barlesi (France)

15.40-15.50: Pembrolizumab in unresectable NSCLC: Rafal Dziadziuszko (Poland)

15.50-16.00: Atezolizumab and tiragolumab in stage III NSCLC: Alessandra Fontecedro Curioni (Svizzera)

16.00-16.10: Options at PACIFIC progression: David Spigel (USA)

16.15-16.45: Lecture: The voice of lung cancer patients: Anne Marie Baird

Program day 2: May 9th, 2022

09.00-11.00: Immunotherapy for NSCLC

Chair: Solange Peters and Lorenza Landi

09.00-09.10: Pembrolizumab or atezolizumab or cemiplimab in PD-L1 >50%: Ed Garon (USA)

09.10-09.20: KEYNOTE 189 and IMPOWER 150: Howard Jack West (USA)

09.20-09.30: EMPOWER Lung 3: M. Gogishvili

09.30-09.40: Tislelizumab for first-line NSCLC: Shun LU (China)

09.40-09.50: Checkmate 9-LA: Tudor Eliade Ciuleanu (Romania)

09.50-10.00: Chemofree options: Checkmate 227 Solange Peters (Switzerland)

10.00-10.10: Chemofree options: POSEIDON Melissa Johnson (USA)

10.10-10.20: KEYNOTE 598: K Park

10.20-10.30: Immunotherapy single agent versus combo: ETOP experience: Rolf Stahel (Switzerland)

10.30-10.40: Tiragolumab and atezolizumab in first-line NSCLC: Delvys Rodriguez-Abreu (Spain)

10.40-10.50: Bevacizumab and atezolizumab: Alessandro Morabito (Italy)

11.00-12.00: Emerging options in immune-pretreated NSCLC

Chair: Federico Cappuzzo and Cesare Gridelli

11.00-11.10: Mechanisms of resistance to immunotherapy: Paola Nisticò (Italy)

11.10-11.20: Novel strategies for overcoming resistance to checkpoint inhibitors: Judy Wang (USA)

11.20-11.30: Sitravatinib for immune-pretreated NSCLC: Ross Soo (Singapur)

11.30-11.40: TEDOPI: Federico Cappuzzo (Italy)

11.40-11.50: Anti-TROP2: Alexander Spira (USA)

12.00-13.00: Between immunotherapy and target therapy-Role of KRAS***Chair: Tony Mok and Ruggero De Maria***

12.10-12.20: KRAS and co-mutations. Impact of STK11 or KEAP1: Ferdinandos Skoulidis (MDACC, Houston)

12.20-12.30: Sotorasib – Silvia Novello (Italy)

12.30-12.40: Adagrasib – Stephen Liu (Georgetown)

12.40-12.50: Emerging agents in KRAS mutated: Paolo Bironzo (Italy)

13.00-14.00: Lunch***14.00-16.00: Target therapies for NSCLC******Chair: Emilio Bria and Paolo Marchetti***

14.00-14.10: FLAURA trial: Pasi Janne (USA)

14.10-14.20: Osimertinib in combination with bevacizumab: Pilar Garrido (Spain)

14.20-14.30: RELAY trial: Updated results and impact of p53 co-mutations: Ed Garon (USA)

14.30-14.40: Drugging exon 20 mutations Rosario Garcia Campelo (Spain)

14.40-14.50: Trastuzumab deruxtecan in HER2 deregulated NSCLC: Egbert Smit (the Netherland)

14.50-15.00: Dabrafenib and trametinib for BRAF mutant patients: David Planchard (Paris)

15.00-15.10: Options for MET exon 14 mutated patients: Oliver Gautschi (Switzerland)

15.10-15.20: Best first-line agent for ALK+ NSCLC: Who is the winner: Tony Mok

15.20-15.30: Options for ROS1+ NSCLC: crizotinib or entrectinib: Lorenza Landi (Roma)

15.30-15.40: Options for NTRK rearranged tumors: Alex Drilon (MSKCC, New York)

15.40-15.50: NRG1: a new target in NSCLC: Gabriele Minuti

16.00-17.00: Small Cell lung cancer, mesothelioma and thymoma

Chair: Andrea Ardizzoni and Sara Pilotto

16.00-16.10: Atezolizumab as first-line therapy in SCLC: Andrea Ardizzoni (Italy)

16.10-16.20: Durvalumab as first-line therapy in SCLC: Luis Paz Ares (Madrid)

16.20-16.30: Second-line options in SCLC: Stephen Liu (Georgetown University)

16.30-16.40: Nivolumab-ipilimumab in mesothelioma: Francesco Grossi (Italy)

16.40-16.50: Second-line therapy in mesothelioma: Dean Fennell

16.50-17.00: Options for Thymomas: Nicolas Girard (France)